Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy-Reference-Cited by-同舟云学术

Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy

Published:2010-06-03 Issue:7 Volume:24 Page:1299-1301
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Giles F J,Abruzzese E,Rosti G,Kim D-W,Bhatia R,Bosly A,Goldberg S,Kam G L S,Jagasia M,Mendrek W,Fischer T,Facon T,Dünzinger U,Marin D,Mueller M C,Shou Y,Gallagher N J,Larson R A,Mahon F-X,Baccarani M,Cortes J,Kantarjian H M

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2010110.pdf

Reference10 articles.

1. Giles FJ, O′Dwyer M, Swords R . Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 2009; 23: 1698–1707.

2. O′Hare T, Eide CA, Deininger MW . Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007; 110: 2242–2249.

3. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009; 27: 6041–6051.

4. Hochhaus A, O′Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009; 23: 1054–1061.

5. Quintas-Cardama A, Kantarjian H, Jones D, Nicaise C, O′Brien S, Giles F et al. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood 2007; 109: 497–499.

Cited by 93 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nilotinib boosts the efficacy of anti-PDL1 therapy in colorectal cancer by restoring the expression of MHC-I;Journal of Translational Medicine;2024-08-14

2. Therapeutic options for chronic myeloid leukemia following the failure of second-generation tyrosine kinase inhibitor therapy;Frontiers in Oncology;2024-07-29

3. Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND study;Leukemia Research;2024-04

4. Impact of TKI Switching, Reduction, and Discontinuation on Cardiovascular Events in cml patients;2023-11-26

5. The importance of personalized medicine in chronic myeloid leukemia management: a narrative review;Egyptian Journal of Medical Human Genetics;2023-04-06